Werewolf Therapeutics Announces Leadership Changes

Ticker: HOWL · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1785530

Werewolf Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyWerewolf Therapeutics, Inc. (HOWL)
Form Type8-K
Filed DateFeb 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, board-of-directors

TL;DR

CMO out, two new directors in at Werewolf Therapeutics.

AI Summary

Werewolf Therapeutics, Inc. announced on February 19, 2025, the departure of its Chief Medical Officer, Dr. Rahul Chaturvedi. The company also reported the election of two new directors, Dr. David R. Boulware and Ms. Sarah E. Kelly, to its Board of Directors.

Why It Matters

Changes in key leadership and board composition can signal shifts in company strategy or operational focus.

Risk Assessment

Risk Level: medium — Leadership changes and board refreshes can introduce uncertainty regarding future strategic direction and execution.

Key Players & Entities

  • Werewolf Therapeutics, Inc. (company) — Registrant
  • Dr. Rahul Chaturvedi (person) — Departing Chief Medical Officer
  • Dr. David R. Boulware (person) — Newly Elected Director
  • Ms. Sarah E. Kelly (person) — Newly Elected Director
  • February 19, 2025 (date) — Date of earliest event reported

FAQ

Who has departed from Werewolf Therapeutics?

Dr. Rahul Chaturvedi, the Chief Medical Officer, has departed from Werewolf Therapeutics.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 19, 2025.

Who are the new members of the Board of Directors?

Dr. David R. Boulware and Ms. Sarah E. Kelly have been elected as new members to the Board of Directors.

What is the principal executive office address for Werewolf Therapeutics?

The principal executive office address is 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472.

What is the company's state of incorporation?

The company's state of incorporation is Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 by Dr. Rahul Chaturvedi regarding Werewolf Therapeutics, Inc. (HOWL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.